[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n LTG8QWG31TZqbor9YWIHUUTlFX6Qzdrqf7618WiuVORVet7m6A2BsONnis8lSJy8\n aBg64HyXe5hjJoHyNY8auQ==\n\n', u'0000950135-04-004199.txt : 20040826\n', u'0000950135-04-004199.hdr.sgml : 20040826\n', u'20040826162313\nACCESSION NUMBER:\t\t0000950135-04-004199\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t2\nCONFORMED PERIOD OF REPORT:\t20040826\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nFILED AS OF DATE:\t\t20040826\nDATE AS OF CHANGE:\t\t20040826\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tIDENIX PHARMACEUTICALS INC\n\t\tCENTRAL INDEX KEY:\t\t\t0001093649\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tPHARMACEUTICAL PREPARATIONS [2834]\n\t\tIRS NUMBER:\t\t\t\t450478605\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t000-49839\n\t\tFILM NUMBER:\t\t04999266\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t60 HAMPSHIRE STREET\n\t\tSTREET 2:\t\t.\n\t\tCITY:\t\t\tCAMBRIDGE\n\t\tSTATE:\t\t\tMA\n\t\tZIP:\t\t\t02139\n\t\tBUSINESS PHONE:\t\t(617) 250-3100\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t60 HAMPSHIRE STREET\n\t\tCITY:\t\t\tCAMBRIDGE\n\t\tSTATE:\t\t\tMA\n\t\tZIP:\t\t\t02139\n\n\tFORMER COMPANY:\t\n\t\tFORMER CONFORMED NAME:\tNOVIRIO PHARMACEUTICALS LTD\n\t\tDATE OF NAME CHANGE:\t19990820\n', u'\n', u'\n', u'8-K\n', u'1\n', u'b51668ipe8vk.htm\n', u'IDENIX PHARMACEUTICALS, INC.\n', u'\n', u'IDENIX PHARMACEUTICALS, INC.', u'\n', u' PAGEBREAK ', u'\n', u'Table of Contents', u'\n', u'\n', u'\n', u'\n', u'SECURITIES AND EXCHANGE COMMISSION', u'\n', u'WASHINGTON, D.C. 20549', u'\n', u'\n', u'\n', u'FORM 8-K', u'\n', u'CURRENT REPORT', u'\n', u'Pursuant to Section\xa013 or 15(d) of the', u'\nSecurities Exchange Act of 1934', u'\n', u'Date of Report (Date of earliest event reported): ', u'August\xa026, 2004', u'\n', u'Idenix Pharmaceuticals, Inc.', u'\n', u'(Exact name of registrant as specified in its charter)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Delaware', u'\n', u'\n', u'\xa0', u'\n', u'000-49839', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'45-0478605', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(State or other jurisdiction\nof incorporation)\n', u'\n', u'\xa0', u'\n', u'(Commission File Number)\n', u'\n', u'\xa0', u'\n', u'(IRS Employer\nIdentification No.)\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'60 Hampshire Street', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cambridge, MA', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'02139', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(Address of principal\nexecutive offices)\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(Zip Code)\n', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'Registrant\x92s telephone number, including area code: ', u'(617)\xa0995-9800', u'\n', u'\n', u'\n', u'\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\n', u' TOC ', u'\n', u'TABLE OF CONTENTS', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Item\xa02.02 Results of Operations and Financial Condition', u'\n', u'SIGNATURE', u'\n', u'EXHIBIT INDEX', u'\n', u'EX-99.1 PRESS RELEASE DATED AUGUST 26, 2004', u'\n', u'\n', u'\n', u' /TOC ', u'\n', u'\n', u'Table of Contents', u'\n', u' link1 "Item&nbsp;2.02 Results of Operations and Financial Condition" ', u'\n', u'\n', u'Item\xa02.02 Results of Operations and Financial Condition', u'\n', u'On August\xa026, 2004, Idenix Pharmaceuticals, Inc. issued a press release\nannouncing its financial results for the second quarter and six months ended\nJune\xa030, 2004. The full text of the press release issued in connection with\nthe announcement is attached as Exhibit\xa099.1 to this Form 8-K.\n\n\n\n', u'\xa0\xa0\xa0\xa0\xa0The information in this Form 8-K and the Exhibit attached hereto is being\n\x93furnished\x94 and shall not be deemed \x93filed\x94 for purposes of Section\xa018 of the\nSecurities Exchange Act of 1934, or the Exchange Act, or otherwise subject to\nthe liabilities of that section, nor shall it be deemed incorporated by\nreference in any filing under the Securities Act of 1933 or the Exchange Act,\nexcept as expressly set forth by specific reference in such filing.\n\n\n', u'2\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'Table of Contents', u'\n', u'\n', u' link1 "SIGNATURE" ', u'\n', u'\n', u'SIGNATURE\n\n\n\n', u'\xa0\xa0\xa0\xa0\xa0Pursuant to the requirements of the Securities Exchange Act of 1934, as\namended, the registrant has duly caused this report to be signed on its behalf\nby the undersigned hereunto duly authorized.\n\n\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Date:      August 26, 2004\xa0', u'\n', u'IDENIX PHARMACEUTICALS, INC', u'.', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'By:\xa0\xa0', u'\n', u'                                /s/ David A. Arkowitz\n\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'David A. Arkowitz\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Chief Financial Officer and Treasurer\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'Table of Contents', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u' link1 "EXHIBIT INDEX" ', u'\n', u'\n', u'EXHIBIT INDEX', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Exhibit', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'No.', u'\n', u'\xa0', u'\n', u'Description', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'99.1\n', u'\n', u'\xa0', u'\n', u'Press Release dated August\xa026, 2004.', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'4\n', u'\n', u'\n', u'\n', u'\n', u'EX-99.1\n', u'2\n', u'b51668ipexv99w1.htm\n', u'EX-99.1 PRESS RELEASE DATED AUGUST 26, 2004\n', u'\n', u'EX-99.1 PRESS RELEASE DATED AUGUST 26, 2004', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'Exhibit\xa099.1', u'\n', u'FOR IMMEDIATE RELEASE', u'\n', u'Contact:', u'\nIdenix Pharmaceuticals, Inc.', u'\nMedia: Teri Dahlman (617)\xa0995-9905', u'\nInvestors: Amy Sullivan (617)\xa0995-9838\n\n\n', u'IDENIX PHARMACEUTICALS ANNOUNCES SECOND QUARTER RESULTS', u'\n', u'Cambridge, MA; August\xa026, 2004 ', u'\x96 Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a\nbiopharmaceutical company engaged in the discovery and development of drugs for\nthe treatment of human viral and other infectious diseases, today reported\nfinancial results for the second quarter and six months ended June\xa030, 2004.\nFor the second quarter ended June\xa030, 2004, Idenix reported total revenues of\n$42.8\xa0million, compared with total revenues of $2.9\xa0million in the second\nquarter of 2003. Total revenues include reimbursements by Novartis of the\nexpenses incurred by Idenix in connection with the development of telbivudine\nand valtorcitabine, Idenix\x92s drug candidates for the treatment of hepatitis B,\namortization of the up-front fee received when Novartis licensed the company\x92s\nhepatitis B drug candidates in May\xa02003, and a $25\xa0million milestone payment by\nNovartis attributable to the results obtained by Idenix in a phase I clinical\ntrial of NM 283, Idenix\x92s lead drug candidate for the treatment of hepatitis C,\nreceived in June\xa02004.\n\n\n', u'Idenix reported net income attributable to common stockholders of\napproximately $21.0\xa0million, or $0.53 per diluted share for the second\nquarter ended June\xa030, 2004, compared to a net loss of approximately $40.9\nmillion, or $1.68 per diluted share in the second quarter of 2003. The\ncompany\x92s profitability for the second quarter ended June\xa030, 2004 was due to\nthe recognition of the $25\xa0million milestone payment received from Novartis.\n\n\n', u'For the six months ended June\xa030, 2004, Idenix reported total revenues of\napproximately $59.5\xa0million, compared with total revenues of approximately\n$3.3\xa0million for the six months ended June\xa030, 2003. Idenix reported net\nincome of approximately $15.1\xa0million, or $0.39 per diluted share for the six\nmonths ended June\xa030, 2004, compared to a net loss of approximately $62.3\nmillion, or $3.94 per diluted share for the six months ended June\xa030, 2003.\nThe profitability experienced by the company for the three and six months\nended June\xa030, 2004 was due to the recognition, during the second quarter, of\nthe $25\xa0million milestone payment received from Novartis. The company does\nnot anticipate maintaining profitability in the near term.\n\n\n', u'\x93We had a successful second quarter, highlighted by the achievement of\nsignificant clinical accomplishments for both telbivudine, our lead drug\ncandidate for the treatment of hepatitis B, and NM 283, a first-in-class drug\ncandidate for the treatment of hepatitis C,\x94 said Jean-Pierre Sommadossi,\nchairman and chief executive officer of Idenix. \x93We look forward to continuing\nthe phase III clinical trial of telbivudine and initiating phase IIb clinical\ntrials for NM 283 and valtorcitabine later this year. Our advancement into\nlate-stage clinical development further supports our belief that our drug\ncandidates have the potential to expand and improve the therapeutic options for\npatients with hepatitis B and hepatitis C.\x94\n\n\n\n', u'- more -\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'Business Highlights', u'\n', u'Idenix\x92s second quarter of 2004 was marked by several significant achievements:\n\n\n\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'In April, the company completed enrollment of its phase III\nclinical trial for telbivudine. More than 1,350 patients at 135 sites\nin 20 countries around the world are enrolled in this clinical trial.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'In May, the company released results of the first human clinical\ntrial of NM 283, a novel once-daily oral treatment for hepatitis C. In\nthis phase I dose escalation clinical trial, NM 283 demonstrated\nconsistent, dose-related antiviral effects in 82 adult patients with\nchronic hepatitis C. As of June\xa030, 2004, the patient cohort that received the highest\noverall dose exposure of NM 283 achieved a mean viral load reduction of\n92\xa0percent, or 1.1 log', u'10', u' copies/ml, within 15\xa0days of treatment. All patients were\ninfected with HCV genotype 1, a difficult to treat strain of virus,\nwhich is the predominant strain in the U.S., Western Europe and Japan,\nand among the NM 283-treated patients, 87\npercent had previously failed interferon-based therapies.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'In June, Idenix received a $25\xa0million milestone payment from\nNovartis based upon the results from the phase I clinical trial of NM\n283.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Idenix also made progress with the clinical development of\nvaltorcitabine, which is being developed as a fixed dose combination\ntherapy with telbivudine for the treatment of hepatitis B. In a phase I\nclinical trial, valtorcitabine was administered at escalating doses once\ndaily for 4\xa0weeks. At the optimal dose of 900 mg, patients achieved a\nmean viral load reduction of more than 3.0 log', u'10', u' copies/ml, or\n99.9 percent, after 28\xa0days of treatment.', u'\n', u'\n', u'\n', u'At June\xa030, 2004, Idenix\x92s cash and cash equivalents totaled $48.6\xa0million. In\nJuly\xa02004, Idenix completed an initial public offering of its common stock,\nwhich combined with a concurrent private placement to Novartis resulted in net\nproceeds to the company of approximately $135\xa0million, after underwriting\ndiscounts. The company\x92s diluted earnings per share for the three-month and\nsix-month periods ended June\xa030, 2004 does not reflect the issuance and sale\nby Idenix of 4,600,000 shares of common stock in the public offering and\n5,400,000 shares of common stock in the concurrent private placement to\nNovartis.\n\n\n', u'About Idenix', u'\nIdenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the\ndiscovery and development of drugs for the treatment of human viral and other\ninfectious diseases. Idenix\x92s current focus is on the treatment of infections\ncaused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus\n(HIV). Idenix\x92s headquarters are located in Cambridge, Massachusetts and it\nhas drug discovery operations in Montpellier, France and Cagliari, Italy. For\nfurther information about Idenix, please refer to http://www.idenix.com.\n\n\n', u'Forward-looking Statements', u'\nThis press release contains \x93forward-looking statements\x94 within the meaning of\nthe Private Securities Litigation Act of 1995. Statements in this press\nrelease other than those that are historical in nature are \x93forward-looking\nstatements.\x94 Such forward looking statements, which include statements with\nrespect to the potential therapeutic benefits and successful development of our\nproducts under development and the company\x92s drug discovery, research and\nclinical development, regulatory approval processes and commercialization\nactivities, are subject to numerous factors, risks and uncertainties that may\ncause actual events or results to differ materially from the company\x92s current\nexpectations. These risks and\nuncertainties relate to the results of clinical trials and other studies with\nrespect to the drug candidates\n\n\n\n', u'- more -\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'that the company has under development, the timing and success of submission,\nacceptance and approval of regulatory filings, the company\x92s dependence on its\ncollaboration with Novartis Pharma AG, the company\x92s ability to obtain\nadditional funding required to conduct its research, development\nand commercialization activities, the ability of the company to attract and\nretain qualified personnel and the company\x92s ability to obtain, maintain and\nenforce patent and other intellectual property protection for its drug\ncandidates and its discoveries. These and other risks are described in greater\ndetail in the \x93Risk Factors\x94 section of the company\x92s final prospectus dated\nJuly\xa021, 2004 and filed with the Securities and Exchange Commission and other\nfilings that the company makes with the Securities and Exchange Commission.\n\n\n', u'All forward-looking statements reflect the company\x92s expectations only as of\nthe date of this release and should not be relied upon as reflecting the\ncompany\x92s views, expectations or beliefs at any date subsequent to the date of\nthis release. Idenix anticipates that subsequent events and developments may\ncause these views, expectations and beliefs to change. However, while Idenix\nmay elect to update these forward-looking statements at some point in the\nfuture, it specifically disclaims any obligation to do so.\n\n\n\n', u'- more -\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'IDENIX PHARMACEUTICALS, INC.', u'\n', u'CONSOLIDATED STATEMENTS OF OPERATIONS', u'\n', u'(IN THOUSANDS, EXCEPT PER SHARE DATA)', u'\n(UNAUDITED)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Three Months Ended June 30,', u'\n', u'\xa0', u'\n', u'Six Months Ended June 30,', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Revenues:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'License fees and collaborative research and\ndevelopment \x96 related party', u'\n', u'\xa0', u'\n', u'$', u'\n', u'42,689', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'7,278', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'59,319', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'7,278', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'License fees and collaborative research and\ndevelopment \x96 other', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(4,469', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(4,165', u'\n', u')', u'\n', u'\n', u'\n', u'Government research grants', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'67', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'110', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'132', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'212', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total revenues', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'42,756', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,919', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'59,451', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,325', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Operating expenses:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Research and development', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,684', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'18,273', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'36,094', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'23,515', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'General and administrative', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,275', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'8,901', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,737', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'12,509', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Sales and marketing', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'912', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'348', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,813', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'679', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'21,871', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'27,522', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'44,644', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'36,703', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Income (loss)\xa0from operations', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'20,885', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(24,603', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'14,807', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(33,378', u'\n', u')', u'\n', u'\n', u'\n', u'Interest income, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'66', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'163', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'144', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'169', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other expense', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(10', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(2', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(15', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Income (loss)\xa0before income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'20,950', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(24,450', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'14,949', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(33,224', u'\n', u')', u'\n', u'\n', u'\n', u'Income tax (provision)\xa0benefit', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(16', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'114', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income (loss)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'20,950', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(24,466', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'15,063', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(33,224', u'\n', u')', u'\n', u'\n', u'\n', u'Accretion of redeemable convertible preferred\nstock', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(16,416', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(29,074', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income (loss)\xa0attributable to common\nstockholders', u'\n', u'\xa0', u'\n', u'$', u'\n', u'20,950', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($40,882', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'15,063', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($62,298', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Earnings (loss)\xa0per share:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.57', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($1.68', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.41', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($3.94', u'\n', u')', u'\n', u'\n', u'\n', u'Diluted', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.53', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($1.68', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.39', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($3.94', u'\n', u')', u'\n', u'\n', u'\n', u'Shares used in calculation of earnings (loss)\xa0per\nshare:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'36,517', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'24,264', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'36,495', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'15,800', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Diluted', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'39,225', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'24,264', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'38,924', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'15,800', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\x96 more \x96\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'IDENIX PHARMACEUTICALS, INC.', u'\n', u'CONDENSED CONSOLIDATED BALANCE SHEETS', u'\n', u'(IN THOUSANDS)', u'\n(UNAUDITED)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'June 30,', u'\n', u'\xa0', u'\n', u'December 31,', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'ASSETS', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash and cash equivalents', u'\n', u'\xa0', u'\n', u'$', u'\n', u'48,611', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'43,485', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts receivable', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'15,168', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,152', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,805', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,717', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'68,584', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'60,354', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Property and equipment, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,710', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,066', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,515', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,670', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total assets', u'\n', u'\xa0', u'\n', u'$', u'\n', u'76,809', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'67,090', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'LIABILITIES AND STOCKHOLDERS\x92 DEFICIT', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts payable and accrued expenses', u'\n', u'\xa0', u'\n', u'$', u'\n', u'17,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'18,535', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Deferred revenue, related party', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,211', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10,756', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other current liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'488', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'664', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total current liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'26,699', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'29,955', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Long-term obligations', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,484', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10,627', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Deferred revenue, related party, net of current position', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'41,452', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'54,239', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'77,635', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'94,821', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Stockholders\x92 deficit', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(826', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(27,731', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total liabilities and stockholders\x92 deficit', u'\n', u'\xa0', u'\n', u'$', u'\n', u'76,809', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'67,090', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'###\n', u'\n', u'\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']